CTSS and viral infectious disease: We compared the efficiency of reducing viral infection (in hiPSC-derived PLOs from diverse donors) using a macropinocytosis-blocking agent (apilimod) vs. a cathepsin-blocking agent (ONO5334) (51) [with a viral replication-blocker, remdesivir (52), as a positive control].